FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1637-1638 April 10, 2008 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Miller, K.

To the Editor: On the basis of an increase in progression-free survival of 5.9 months, Miller et al. (Dec. 27, 2007, issue)¹ imply that the addition of bevacizumab to paclitaxel is a significant advance in the treatment of metastatic breast cancer. However, progression-free survival is an unreliable measure of benefit in metastatic cancer, and patients given bevacizumab do not live longer than patients given paclitaxel alone. Furthermore, it is questionable to cite response rates in phase 3 studies, since response rates are a means of looking for active new agents in phase 2 studies. Finally, there are no data that . . . [Full Text of this Article]

This article has been cited by other articles:

• Haines, I. E. (2008). Dose Selection in Phase I Studies: Why We Should Always Go for the Most Effective. JCO 26: 3650-3652 [Full Text]